Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Polycythemia Vera Pipeline Report 2016 - Review of 12 Companies & 15 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Polycythemia Vera pipeline therapeutics constitutes close to 15 molecules. which approximately 15 molecules are developed by Companies. Our latest report Polycythemia Vera - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Polycythemia Vera Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 4 and 5 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Polycythemia Vera Overview
  3. Therapeutics Development
  4. Pipeline Products for Polycythemia Vera - Overview
  5. Pipeline Products for Polycythemia Vera - Comparative Analysis
  6. Polycythemia Vera - Therapeutics under Development by Companies
  7. Polycythemia Vera - Therapeutics under Investigation by Universities/Institutes
  8. Polycythemia Vera Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Polycythemia Vera - Products under Development by Companies
  13. Polycythemia Vera - Products under Investigation by Universities/Institutes
  14. Polycythemia Vera - Companies Involved in Therapeutics Development
  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • PharmaEssentia Corporation
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/j3hxbl/polycythemia_vera

Related Topics: Hematological Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005876/en/

Business Wire
www.businesswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.